E6446

• Description :

  E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD) -fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) [1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Stearoyl-CoA Desaturase (SCD) ; Toll-like Receptor (TLR)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/e6446.html

• Concentration :

  10mM

• Purity :

  98.78

• Solubility :

  DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  C1(C2=CC=C(OCCCN3CCCC3)C=C2)=NC4=CC=C(OCCCN5CCCC5)C=C4O1

• Molecular Formula :

  C27H35N3O3

• Molecular Weight :

  449.59

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85 (3) :429-40.|[2]Franklin BS, et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc Natl Acad Sci U S A. 2011 Mar 1;108 (9) :3689-94.|[3]Wang W, et al. Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: critical role of liver-adipose axis. Cell Commun Signal. 2023 Sep 30;21 (1) :268.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  TLR7; TLR9

• Citation 01 :

  Cell Rep. 2025 Jun 13;44 (6) :115851.|Infect Immun. 2019 Dec 17;88 (1) :e00697-19.|J Virol. 2025 Jun 12:e0069025.|Oxid Med Cell Longev. 2019 Apr 28:2019:6527638.|SSRN. 2025 Sep 10.|Cell Commun Signal. 2023 Sep 30;21 (1) :268.|Patent. US20210388060A1.|Research Square Preprint. 2021 Mar.|Vet Microbiol. 2017 Aug:207:56-62.

• CAS Number :

  [1219925-73-1]